bioMérieux S.A. (BIM.PA)
| Previous Close | 98.35 |
| Open | 98.35 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 96.50 - 98.50 |
| 52 Week Range | 88.25 - 111.50 |
| Volume | |
| Avg. Volume | 105,262 |
| Market Cap | 11.527B |
| Beta (5Y Monthly) | 0.22 |
| PE Ratio (TTM) | 27.98 |
| EPS (TTM) | 3.47 |
| Earnings Date | Oct 30, 2024 |
| Forward Dividend & Yield | 0.85 (0.86%) |
| Ex-Dividend Date | Jun 07, 2024 |
| 1y Target Est | 118.01 |
PR NewswireGlobal In Vitro Diagnostics Leader bioMérieux Celebrates the Opening of the Molecular and Genomic Innovation Center at the Navy Yard in Philadelphia
bioMérieux, a world leader in in vitro diagnostics, celebrates the opening of the company's Molecular and Genomic Innovation Center. The new 32,000 sq. ft. facility is home to the xPRO™ Program, which has rapidly changed the landscape of food safety diagnostic capabilities by partnering directly with industry leaders to address unmet needs to streamline operational efficiencies and further public health. bioMérieux's global leadership team was on-site for the ribbon cutting event, as Philadelphi
- Reuters
UPDATE 2-Slide in defence stocks knocks down Europe's STOXX 600
A sell-off in defence stocks dragged Europe's benchmark stock index lower on Tuesday, while investors braced for this week's crucial U.S. inflation data and the European Central Bank's monetary policy decision. Benchmark indexes in Germany, France and Italy lost between 0.9% and 1.3%. Defence-related stocks like Sweden's SAAB, Italy's Leonardo, Germany's Rheinmetall and France's Thales were among the top laggards on the STOXX 600, down between 4.9% and 9.8%.
